Skip Nav Destination
Issues
1 June 2005
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Issue Sections
ARTICLE
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors
David E. Weng; Paul A. Masci; Susan F. Radka; T. Elise Jackson; Patricia A. Weiss; Ram Ganapathi; Paul J. Elson; William B. Capra; Vann P. Parker; Jennifer A. Lockridge; J. Wayne Cowens; Nassim Usman; Ernest C. Borden
Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein
Hyun-Mi Cho; Joseph D. Rosenblatt; Young-Sook Kang; M. Luisa Iruela-Arispe; Sherie L. Morrison; Manuel L. Penichet; Young-Guen Kwon; Tae-Woong Kim; Keith A. Webster; Hovav Nechustan; Seung-Uon Shin
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
Yan Luo; Alexander R. Shoemaker; Xuesong Liu; Keith W. Woods; Sheela A. Thomas; Ron de Jong; Edward K. Han; Tongmei Li; Vincent S. Stoll; Jessica A. Powlas; Anatol Oleksijew; Michael J. Mitten; Yan Shi; Ran Guan; Thomas P. McGonigal; Vered Klinghofer; Eric F. Johnson; Joel D. Leverson; Jennifer J. Bouska; Mulugeta Mamo; Richard A. Smith; Emily E. Gramling-Evans; Bradley A. Zinker; Amanda K. Mika; Phong T. Nguyen; Tilman Oltersdorf; Saul H. Rosenberg; Qun Li; Vincent L. Giranda
The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer
Christopher J. Sweeney; Sanjana Mehrotra; Miral R. Sadaria; Suresh Kumar; Nicholas H. Shortle; Yaritzabel Roman; Carol Sheridan; Robert A. Campbell; Daryl J. Murry; Sunil Badve; Harikrishna Nakshatri
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.